VEA
TCRT icon

Virtus ETF Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Virtus ETF Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-876
Closed -$86K – 473
2022
Q1 		$86K Sell
876
-52
-6% -$6.67K 0.04% 328
2021
Q4 		$152K Buy
928
+448
+93% +$98.4K 0.06% 344
2021
Q3 		$131K Sell
480
-26
-5% -$7.95K 0.06% 363
2021
Q2 		$200K Sell
506
-142
-22% -$66.3K 0.08% 348
2021
Q1 		$350K Buy
648
+12
+2% +$7.47K 0.15% 208
2020
Q4 		$241K Sell
636
-25
-4% -$9.94K 0.1% 324
2020
Q3 		$250K Sell
661
-90
-12% -$39.8K 0.13% 263
2020
Q2 		$369K Buy
751
+265
+55% +$118K 0.17% 240
2020
Q1 		$179K Sell
486
-71
-13% -$36.7K 0.07% 282
2019
Q4 		$394K Buy
557
+234
+72% +$161K 0.06% 263
2019
Q3 		$207K Sell
323
-18
-5% -$14.3K 0.04% 243
2019
Q2 		$298K Sell
341
-273
-44% -$188K 0.06% 217
2019
Q1 		$355K Sell
614
-72
-10% -$30.1K 0.76% 46
2018
Q4 		$192K Sell
686
-53
-7% -$21K 0.03% 178
2018
Q3 		$355K Sell
739
-528
-42% -$226K 0.04% 176
2018
Q2 		$574K Buy
1,267
+84
+7% +$53.3K 0.51% 134
2018
Q1 		$695K Buy
1,183
+638
+117% +$398K 0.6% 95
2017
Q4 		$338K Buy
545
+152
+39% +$109K 0.42% 105
2017
Q3 		$362K Buy
393
+36
+10% +$32K 0.05% 120
2017
Q2 		$333K Buy
357
+59
+20% +$57.8K 0.05% 95
2017
Q1 		$283K Buy
298
+29
+11% +$27K 0.05% 144
2016
Q4 		$216K Buy
269
+1
+0.4% +$901 0.06% 170
2016
Q3 		$226K Hold
268
– – 0.11% 130
2016
Q2 		$221K Buy
268
+75
+39% +$81.7K 0.16% 125
2016
Q1 		$215K Buy
+193
New +$198K 0.3% 76

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtus ETF Advisers's TCRT Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 876 shares — an estimated $86K sold.

Virtus ETF Advisers first reported a position in TCRT in Q1 2016 and held it in 25 quarters. The position peaked at $695K in Q1 2018. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 876 Alaunos Therapeutics shares in Q2 2022, an estimated $86K.
  • Virtus ETF Advisers first reported a position in Alaunos Therapeutics in Q1 2016 and held it in 25 quarters.
  • Virtus ETF Advisers's Alaunos Therapeutics position peaked at $695K in Q1 2018.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.